Next Article in Journal
Antiproliferative Activity of Triterpenoid and Steroid Compounds from Ethyl Acetate Extract of Calotropis gigantea Root Bark against P388 Murine Leukemia Cell Lines
Previous Article in Journal
Liquid Chromatographic Fingerprints for the Characterization of Flavanol-Rich Nutraceuticals Based on 4-Dimethylaminocinnamaldehyde Precolumn Derivatization
Review

Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review

1
Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia
2
Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia
3
Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran—Hasan Sadikin Hospital, Bandung 40161, Indonesia
4
Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, 6255HB Nijmegen, The Netherlands
*
Author to whom correspondence should be addressed.
Academic Editor: Roman B. Lesyk
Sci. Pharm. 2021, 89(2), 19; https://doi.org/10.3390/scipharm89020019
Received: 22 February 2021 / Revised: 4 May 2021 / Accepted: 11 May 2021 / Published: 18 May 2021
Multidrug-resistant tuberculosis (MDR-TB) is an infectious disease caused by Mycobacterium tuberculosis which is resistant to at least isoniazid and rifampicin. This disease is a worldwide threat and complicates the control of tuberculosis (TB). Long treatment duration, a combination of several drugs, and the adverse effects of these drugs are the factors that play a role in the poor outcomes of MDR-TB patients. There have been many studies with repurposed drugs to improve MDR-TB outcomes, including clofazimine. Clofazimine recently moved from group 5 to group B of drugs that are used to treat MDR-TB. This drug belongs to the riminophenazine class, which has lipophilic characteristics and was previously discovered to treat TB and approved for leprosy. This review discusses the role of clofazimine as a treatment component in patients with MDR-TB, and the drug’s properties. In addition, we discuss the efficacy, safety, and tolerability of clofazimine for treating MDR-TB. This study concludes that the clofazimine-containing regimen has better efficacy compared with the standard one and is also well-tolerated. Clofazimine has the potential to shorten the duration of MDR-TB treatment. View Full-Text
Keywords: clofazimine; MDR-TB; efficacy; safety; tolerability clofazimine; MDR-TB; efficacy; safety; tolerability
Show Figures

Figure 1

MDPI and ACS Style

Nugraha, R.V.; Yunivita, V.; Santoso, P.; Aarnoutse, R.E.; Ruslami, R. Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review. Sci. Pharm. 2021, 89, 19. https://doi.org/10.3390/scipharm89020019

AMA Style

Nugraha RV, Yunivita V, Santoso P, Aarnoutse RE, Ruslami R. Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review. Scientia Pharmaceutica. 2021; 89(2):19. https://doi.org/10.3390/scipharm89020019

Chicago/Turabian Style

Nugraha, Rhea V.; Yunivita, Vycke; Santoso, Prayudi; Aarnoutse, Rob E.; Ruslami, Rovina. 2021. "Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review" Sci. Pharm. 89, no. 2: 19. https://doi.org/10.3390/scipharm89020019

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop